Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product sales <li /> SYFOVRE® (pegcetacop ...

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product ...

Combination rituximab and IVIG therapy may be a viable treatment option for patients with refractory autoimmune diseases, though the quality of evidence is low.

In a strikingly vulnerable entry of her weekly newsletter Sincerely, Vivy, FashionValet co-founder Vivy Yusof opened up about ...

Researchers reviewed the potential for links between age-related macular degeneration and immune-mediated inflammatory ...